Objective-To examine the robustness of the association between C-reactive protein (CRP) levels and increased risk of venous thromboembolism (VTE) and to examine whether genetically elevated CRP levels cause VTE. Methods and Results-In the prospective Copenhagen City Heart Study, we observed 10 388 participants for longer than 16 years, of whom 484 developed a VTE. In the cross-sectional Copenhagen General Population Study, we studied 36 616 participants, of whom 903 previously had a VTE. Levels of CRP greater than 3 mg/L versus less than 1 mg/L were associated with a 2.3-and 2.4-fold increased risk of VTE in the Copenhagen City Heart Study and the Copenhagen General Population Study, respectively. CRP levels in tertiles, quintiles, and octiles associated with a stepwise increase in VTE risk. CRP genotypes associated with an increase in plasma CRP levels up to 59% but did not associate consistently with risk of VTE in either study. The causal odds ratio for VTE for a doubling in genetically elevated CRP on instrumental variable analyses was lower than the odds ratio for VTE observed for a doubling in plasma CRP on logistic regression ([odds ratio and 95% CI] 0.80 [0.56 to 1.12] versus 1.17 [1.08 to 1.27]; Pϭ0.04). Conclusion-We observed 47 000 participants from the general population, of whom 1387 developed VTE. Although elevated CRP levels robustly associated with increased risk of VTE, this may not necessarily be a causal association because genetically elevated CRP did not associate with VTE risk. (Arterioscler Thromb Vasc Biol. 2010;30:1672-1678.)
T he recent "Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin" (JUPITER) showed a 43% reduced risk of venous thromboembolism (VTE) in response to rosuvastatin, 20 mg/d, in healthy individuals with relatively low levels of low-density lipoprotein (LDL) cholesterol but with slightly elevated levels of C-reactive protein (CRP). 1 This was a novel and somewhat surprising finding, particularly because the mechanism behind this effect is unclear.
The JUPITER study also demonstrated a 50% reduction in LDL cholesterol, a 37% reduction in CRP levels, and a 44% reduction in the primary composite end point, including arterial thrombotic events. 2 Because elevated CRP levels are not likely to be causally related to increased risk of arterial thrombosis, 3, 4 the effect of rosuvastatin on reduced risk of arterial thrombosis is likely caused by the LDL reduction. 5 This leads to reduced flux of LDL into the arterial wall, reduced inflammation in atherosclerotic plaques, and subsequent reduced plasma CRP levels. However, because a reduction in LDL cholesterol is unlikely to cause the observed reduction in VTE in JUPITER, 1 it is possible that the reduction in CRP levels in JUPITER could be the driving force behind the reduced VTE risk. If so, this would imply that elevated CRP levels are causally related to increased risk of VTE. Whether this is the case is unclear. 6 -11 To explore whether elevated CRP levels are causally associated with VTE, first we examined the robustness of the association between the 2 features; second, using a Mendelian randomization design, we tested whether genetically elevated levels of CRP increased the risk of VTE.
Methods
The studies were approved by Herlev Hospital and by Danish ethical committees, and were conducted according to the Declaration of Helsinki.
Study Cohorts
The 2 cohorts (1 prospective and 1 cross-sectional) studied were white individuals of Danish descent and were independent of each other. Participants were recruited by invitation letter to a health examination based on The Danish Central Person Registration number in either study. We included all eligible persons and had no exclusion criteria, except ethnicity other than Danish. Written informed consent was obtained from participants. Each participant completed a questionnaire that was validated by an investigator at the health examination. This examination included measurement of cardiovascular risk factors, as described later.
The Copenhagen City Heart Study (CCHS) 3, 12 is a prospective study of individuals randomly selected from the population of Copenhagen. From this study, 10 388 participants were included in the present analysis. These persons participated in the 1991 to 1994 examination (16 563 were invited, and 10 135 participated; 9280 gave blood for DNA analyses and underwent genotyping for all 4 polymorphisms; the genotyping success rate was Ͼ99.9%) and/or in the 2001 to 2003 examination (12 600 were invited, and 6238 participated; 1108 new persons gave blood for DNA analyses and underwent genotyping for all 4 polymorphisms; the genotyping success rate was Ͼ99.9%). We used diagnoses registered in 1976 through July 2007 from the national Danish Patient Registry and the national Danish Causes of Death Registry on deep venous thrombosis and pulmonary embolism, and individuals with either event were coded as having VTE. 13 In the CCHS, these exact same end points were previously used to demonstrate a 3-and 18-fold increased risk of VTE in Factor V Leiden heterozygotes and homozygotes versus noncarriers. Also, among 176 medical records with a discharge International Classification of Diseases code for VTE, 72% of cases met the objective diagnostic criteria: the diagnostic criteria used were ultrasonography or venography in the case of deep venous thrombosis and ventilation-perfusion scintigraphy in the case of pulmonary embolism. 13 The Copenhagen General Population Study (CGPS) 3, 12 is a crosssectional study of individuals selected, such as those in the CCHS, from the population of Copenhagen. From this study, we included 36 616 participants in the present analysis, with VTE ascertained as previously described from 1976 through July 2007. These persons participated in the 2003 to 2007 examination (79 698 were invited, and 37 214 participated; 36 616 gave blood and underwent genotyping; the genotyping success rate was Ͼ99.9%).
Genotyping and Biochemical Analyses
A commercially available system (ABI PRISM 7900HT Sequence Detection System; Applied Biosystems Inc, Foster City, Calif) was used to genotype for 4 single-nucleotide polymorphisms (SNPs) in the CRP gene (rs3091244, rs1130864, rs1205, and rs3093077). 3 Genotyping was verified by DNA sequencing in more than 30 individuals with each genotype.
High-sensitivity CRP was measured using nephelometry in the first 23 827 individuals of the CGPS (Dade Behring, Deerfield, Ill) or turbidimetry in the last 13 387 individuals of the CGPS and in the CCHS (Dako, Glostrup, Denmark); the coefficient of variation from month to month, based on daily measurement of the same samples, ranged from 3% to 8%. In the CGPS, we initially stratified main statistical analyses on whether CRP was measured with the Dade Behring or the Dako method. However, because the results were similar in those measured with either assay and similar to the results observed in participants in the CCHS measured with the Dako assay, all statistical analyses in this article are presented for the entire CGPS, irrespective of assay used. All participants with available plasma had CRP levels measured. CRP levels were classified as low (Ͻ1.0 mg/L), average (1.0 to 3.0 mg/L), or high (Ͼ3.0 mg/L). Total cholesterol, LDL cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured using standard hospital assays (Boehringer Mannheim, Mannheim, Germany; or Konelab, Helsinki, Finland). LDL cholesterol was calculated using the Friedewald equation if triglycerides were less than 4 mmol/L (352 mg/dL) but measured directly at higher triglyceride levels.
Other Covariates
Body mass index was expressed as weight in kilograms divided by height in meters squared; blood pressure was also measured. Hypertensive patients comprised those with a diastolic blood pressure of 90 mm Hg or higher, those with a systolic blood pressure of 140 mm Hg or higher, and/or those taking antihypertensive medication. Patients with diabetes mellitus had a nonfasting blood glucose level of greater than 11 mmol/L, were receiving insulin treatment, or were receiving any other antidiabetic treatment. Smoking was classified into ever and never smokers. Lipid-lowering treatment was self-reported statin treatment; in the CCHS, we used updated values (time-varying exposure) from the 1991 to 1994 and the 2001 to 2003 examinations; in the CGPS, only the information from the 2003 to 2007 examination was available. Physical inactivity was defined as fewer than 2 hours of physical activity per week, at work and during leisure time; whereas physical activity was defined as 2 hours or more of physical activity per week, at work and during leisure time.
Statistical Analyses
We used computer software (Stata 10.1; StataCorp, College Station, Tex) for all analyses. From the 4 CRP polymorphisms, we generated all possible genotype combinations and ranked the 9 most common combinations according to increasing plasma CRP levels. For trend tests, the different groupings of subjects by plasma CRP levels, CRP genotype, or genotype combination were coded numerically (ie, 1, 2, 3, and so on) according to increasing CRP levels.
First, we analyzed the relationship between plasma CRP levels and risk of VTE in the prospective CCHS with the use of left truncation (or delayed entry) from the 1991 to 1994 examination. 14 Cox regression models with age as the time scale were used to estimate hazard ratios for VTE, adjusting for age, sex, and statin use, or additionally for genotype or multifactorially. Afterwards, we confirmed the relationship between plasma CRP levels and risk of VTE in the cross-sectional CGPS, using a logistic regression model adjusting for age, sex, and statin use, or additionally for genotype or multifactorially.
Second, to further explore the robustness of the association between CRP levels and VTE risk, individuals were divided into groups by CRP in tertiles, quintiles, and octiles in the combined study of the CCHS and the CGPS to achieve maximal statistical power. Logistic regression models that adjusted for age, sex, and statin use, or additionally for genotype or multifactorially, were used to estimate odds ratios.
Third, to explore whether genetically elevated CRP levels cause VTE, we determined the associations between the 4 CRP SNP genotypes (rs1205, rs1130864, rs3091244, and rs3093077) individually and as genotype combinations and risk of VTE. These genotypes and genotype combinations are known to increase plasma CRP levels 3 ; based on these increases, we also calculated a theoretically predicted risk of VTE (ie, the expected VTE risk if CRP was causally associated with VTE).
Last, based on the associations between CRP genotype combination and plasma CRP levels, and between CRP genotype combination and VTE risk, we used instrumental variable analysis to estimate the association between a doubling of genetically elevated levels of CRP and VTE risk. Thus, we used generalized least-squares regression. 15 This estimated causal effect of CRP on VTE risk was compared with the observed association between a doubling in plasma CRP levels and VTE risk. 16 For Cox regression analyses, we tested the assumption of proportional hazards graphically by plotting of log (cumulative hazard) as a function of age. Suspicion of nonparallel lines was tested by using Schoenfeld residuals. We detected no major violations of the proportional hazards assumption.
Results
The selected clinical characteristics of participants in the study cohorts are shown in Table 1 . The same clinical characteristics are shown as a function of CRP genotype combinations in the supplemental Table (available online at http://atvb.ahajournals.org). There were no differences as function of CRP genotype combinations or as a function of the 4 polymorphisms individually (data not shown). Table 2 shows increasing plasma CRP levels as a function of CRP genotype combinations.
Plasma CRP Level and Risk of VTE
First, we observed that CRP measured as long as 16 years ago in the prospective CCHS and divided into more than 3 mg/L versus less than 1 mg/L associated with an increased risk of VTE of 2.3-fold (95% CI, 1.3 to 4.4-fold), after adjustment for age, sex, and use of statins (Figure 1, left) . The results were essentially unchanged by further adjusting for CRP genotype but became insignificant after multifactorial adjustment (Figure 1, left) . In the large cross-sectional CGPS, CRP levels of more than 3 mg/L, compared with levels of less than 1 mg/L, were associated with a 2.4-fold (95% CI, 1.9-to 2.9-fold) increased risk of VTE after adjustment for age, sex, and use of statins (Figure 1, right) , thus confirming the results from the CCHS. This estimate remained significant after multifactorial adjustment, although it was slightly attenuated to 1.8 (95% CI, 1.4 to 2.2) (Figure 1, right) . The probability values for trend in both studies were Ͻ0.001, with the exception of multifactorial adjustment in the CCHS (PϽ0.05 for trend). Although the CGPS mainly is a cross-sectional study, we observed all participants for VTE events from 1976 through July 2007; irrespective of whether the VTE occurred before or after the CRP measurement, CRP levels of more than 3 mg/L, compared with levels of less than 1 mg/L, were associated with similar risk increases (Supplemental Figure I) .
Second, after combining the 2 studies for maximal statistical power, CRP levels in tertiles, quintiles, and octiles associated with a stepwise increase in VTE risk for stepwise increases in CRP levels, regardless of adjustment for age, sex, and statin use or multifactorial adjustment (PϽ0.001 for trend) (Figure 2 , both left and right). When adjusting for age, sex, and use of statins (Figure 2, left) , CRP levels in the highest versus the lowest tertile associated with a 2.2-fold (95% CI, 1.9-to 2.5-fold) increased VTE risk; CRP levels in (Figure 2 ). Multifactorial adjustment attenuated these risk estimates only slightly ( Figure   2 , right). Irrespective of whether VTE occurred in those with or without cancer or in those with or without statin use, CRP levels of greater than 3 mg/L, compared with levels of less than 1 mg/L, were associated with similar risk increases (Supplemental Figure II) .
Table 2. CRP Levels by CRP Genotype Combinations in the Combined Copenhagen City Heart Study and Copenhagen General Population Study
CRP Genotype Combinations #1 #2 #3 #4 #5 #6 #7 #8 #9 rs1205, *1081 GϾA A A G A G G G A G G G A G G G G G G rs1130864, *223 CϾT C C C C C C C T C T C C T T C C C T rs3091244, Ϫ390 CϾTϾA C C C C C C C T C T C A T T C A A T
rs3093077, *3678 TϾG T T T T T T T T T T G T T T G T G T
Risk of incident and prevalent VTE as a function of plasma CRP (P-CRP) level: less than 1, 1 to 3, and more than 3 mg/L. In the prospective CCHS, CRP levels were measured in participants at the 1991 to 1994 examination and subsequently followed up to 16 years for incident VTE (left). In the cross-sectional CGPS, CRP levels were measured in participants at the 2003 to 2007 examination (right). Multifactorial adjustment was for all covariates listed in Table 1 .
Figure 2.
Risk of VTE as a function of plasma CRP (P-CRP) level in tertiles, quintiles, or octiles. To achieve maximal statistical power, data from the CCHS and the CGPS were combined. Multifactorial adjustment was for all covariates listed in Table 1 .
Genetically Elevated CRP Level and Risk of VTE
Third, looking at the 4 SNPs in the CRP gene alone (rs1205, rs1130864, rs3091244, and rs3093077) or the genotype combinations of the 4 SNPs based on their effect on CRP levels ( Table 2) , risk of VTE was not associated consistently with SNP genotype or genotype combinations in either study (Figure 3 ). If we assume that an elevation in CRP is causally associated with VTE risk, then genetically elevated CRP levels should confer the same increase in VTE risk as that observed for a similar increase in plasma CRP levels in the general population. Based on this assumption, we estimated that the 59% increment in plasma CRP levels as the result of CRP genotype combinations would predict an increased VTE risk of up to 8% (odds ratio, 1.08; 95% CI, 1.01 to 1.15) ( Figure 4 ). However, for the combined studies, risk of VTE was not increased for any CRP genotype combination. Last, by use of instrumental variable analyses based on the odds ratios for VTE for the 9 CRP genotype combinations and ranked according to increasing CRP levels ( Table 2) , we Table) . Odds ratios for the predicted risk were adjusted for age, sex, and use of statins, whereas odds ratios for the observed risk were crude. To achieve maximal statistical power, data from the CCHS and the CGPS were combined (1370 patients with VTE and 45 100 controls). estimated a regression to illustrate the connection between the genotype combinations, genetically elevated plasma CRP levels, and risk of VTE (supplemental Figure III) . The causal odds ratio for VTE associated with a doubling in genetically elevated CRP level on instrumental variable analysis was lower than the odds ratio for VTE observed for a doubling in plasma CRP level on logistic regression (0.80 [95% CI, 0.56 to 1.12] versus 1.17 [1.08 to 1.17]; Pϭ0.04).
Discussion
We found that increased levels of plasma CRP associated robustly with increased risk of VTE; however, because genetically elevated CRP levels did not associate with increased VTE risk, this may not necessarily appear to be a causal association. The fact that elevated CRP levels robustly associate with increased risk of VTE, which is also supported by other studies, 7, 11 rather suggests that an increased inflammatory state is present in those experiencing a VTE. One study 17 with only 37 VTE events failed to show an association between elevated plasma CRP levels and increased risk of VTE; however, this negative finding is likely explained by limited statistical power compared with the present study.
Inflammatory processes may affect VTE risk because a procoagulant state may be induced by proinflammatory cytokines and chemokines, stimulating monocytes to produce tissue factor. 18 Even though VTE is not characterized as a chronic systemic inflammatory disease, such as atherosclerosis, an inflammatory response, regardless of its origin, could lead to hypercoagulability and increase the risk of VTE. This would go well in line with the finding of a peak in CRP levels around the VTE event. 8 Mean CRP levels were higher in patients with VTE than in controls, independent of the time elapsed since the VTE event, suggesting that inflammation was more prominent among the VTE cases than among the controls. 19 This may especially be the case in patients who have idiopathic VTE compared with secondary VTE, possibly linking inflammation closer to idiopathic VTE. 20 Nevertheless, we found similar associations between elevated CRP and VTE risk in those with and without cancer, a typical cause of secondary VTE.
In the JUPITER trial, the lower risk of VTE in the rosuvastatin-versus placebo-treated group 1 could be caused by an antiinflammatory effect, through modifications of liver protein synthesis or alterations in cytokine production released by leukocytes or adipose tissue, or by an anticoagulant effect. [21] [22] [23] The present study suggests that it is not the 37% reduced CRP levels per se that cause reduced VTE risk in the statin-treated patients; thus, it seems more likely that reduced generalized inflammation detected as reduced CRP levels may explain the reduced VTE risk in JUPITER. The simplest possible explanation seems to be that the 50% reduction in LDL cholesterol levels in the rosuvastatin-versus placebotreated group leads to a reduced flux of LDL particles from plasma into the arterial intima 24 and to less inflammation in atherosclerotic plaques. 5 This would secondarily lead to an overall reduced inflammatory response, a reduced propensity for coagulation to occur, and a reduced risk of VTE observed. Interestingly, we found similar associations between an elevated CRP level and VTE risk in those who do and do not use statins; however, simvastatin, 40 mg/d, is the most commonly used statin dose in Denmark and is less potent than the 20-mg/d rosuvastatin dose that was used in the JUPITER trial.
In the present study, the question of causality between elevated CRP levels and increased VTE risk was addressed using genotypes and avoiding confounding and reverse causation in the study design termed "Mendelian randomization." 25 Therefore, conventional VTE risk factors and other cardiovascular risk factors were not associated with CRP genotype or CRP genotype combinations in the present study. By using this design, our finding of lack of association between CRP genotype and CRP genotype combinations and risk of VTE is supported by other studies. 26 -28 Thus, as previously mentioned, a lifelong increase in CRP levels does not play a role in the pathogenesis of VTE.
The strengths of this study include that we used the large prospective CCHS with almost 10 000 participants and follow-up for up to 16 years and the even larger crosssectional CGPS with more than 35 000 participants. Also, because of the complete Danish registries, we had 100% follow-up (ie, we did not lose track of even a single individual). Finally, because we included only people of Danish descent, admixture is not a problem in the genetic part of our studies.
A limitation of our study includes that we only studied whites of Danish descent and, therefore, caution should be applied when extrapolating these results to other ethnicities. Also, the inherent limitations in the Mendelian randomization design 29, 30 and statistical power should be considered. In addition, residual confounding by covariates that are measured imprecisely represents a limitation, exactly like unmeasured potential confounders such as drugs and other comorbidities. There were few statin users at baseline, so the CRP values assessed at baseline were before statin use for most participants who experienced VTE after baseline. Most cases of VTE were not validated by medical record review and, therefore, the observed associations are likely to be underestimated. This needs to be considered in relation to the investigation of causality for the CRP gene. Finally, we were not able to distinguish completely between idiopathic and secondary VTE, which may limit our ability to fully understand the relationship between CRP, inflammation, and VTE.
In conclusion, although elevated CRP levels robustly associate with increased risk of VTE, this may not necessarily be a causal association. It seems more likely that the inflammatory state seen in VTE is a consequence of an underlying causal pathway, also leading to a hypercoagulant state and eventually to VTE.
